| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.16▼ | 2.17▼ | 2.17▼ | 2.05▲ | 2.22▼ |
| MA10 | 2.18▼ | 2.17▼ | 2.17▼ | 1.97▲ | 2.26▼ |
| MA20 | 2.17▼ | 2.17▼ | 2.13▲ | 2.10▲ | 2.09▲ |
| MA50 | 2.16▼ | 2.03▲ | 1.98▲ | 2.22▼ | 1.99▲ |
| MA100 | 2.05▲ | 1.99▲ | 2.02▲ | 2.10▲ | 2.93▼ |
| MA200 | 1.99▲ | 2.18▼ | 2.21▼ | 1.80▲ | 4.07▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.011▼ | -0.006▼ | 0.016▲ | 0.000▼ |
| RSI | 48.548▼ | 55.287▲ | 59.542▲ | 50.311▲ | 50.033▲ |
| STOCH | 31.895 | 47.727 | 39.773 | 73.573 | 57.245 |
| WILL %R | -77.778▼ | -63.636 | -50.000 | -24.135▲ | -53.435 |
| CCI | -71.893 | -50.725 | -38.590 | 146.257▲ | -17.354 |
|
Saturday, March 15, 2025 07:34 AM
Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) today and set a price target of ...
|
|
Friday, March 14, 2025 05:26 AM
Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...
|
|
Friday, March 14, 2025 04:50 AM
Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/03/25 | 2.25 | 2.2899 | 2.10 | 2.11 | 333,506 |
| 13/03/25 | 2.14 | 2.21 | 2.07 | 2.20 | 246,017 |
| 12/03/25 | 1.95 | 2.1646 | 1.92 | 2.11 | 169,514 |
| 11/03/25 | 1.86 | 1.95 | 1.81 | 1.95 | 162,459 |
| 10/03/25 | 1.90 | 1.9999 | 1.78 | 1.86 | 245,556 |
| 07/03/25 | 1.97 | 1.97 | 1.81 | 1.88 | 127,820 |
| 06/03/25 | 1.80 | 1.8893 | 1.78 | 1.80 | 114,557 |
| 05/03/25 | 1.965 | 1.9893 | 1.5445 | 1.85 | 310,428 |
| 04/03/25 | 1.86 | 2.05 | 1.67 | 1.94 | 368,422 |
| 03/03/25 | 2.12 | 2.13 | 1.92 | 1.95 | 201,861 |
|
|
||||
|
|
||||
|
|